1 Kagajora

Rothfus Committee Assignments 1

Analysis

Legislative Metrics

Read our 2017 Report Card for Rothfus.

Ideology–Leadership Chart

Rothfus is shown as a purple triangle ▲ in our ideology-leadership chart below. Each dot is a member of the House of Representatives positioned according to our liberal–conservative ideology score (left to right) and our leadership score (leaders are toward the top).

The chart is based on the bills Rothfus has sponsored and cosponsored. See full analysis methodology.

Ratings from Advocacy Organizations

Committee Membership

Keith Rothfus sits on the following committees:

Enacted Legislation

Rothfus was the primary sponsor of 1 bill that was enacted:

View All »

We consider a bill enacted if one of the following is true: a) it is enacted itself, b) it has a companion bill in the other chamber (as identified by Congress) which was enacted, or c) if about one third or more of its provisions were incorporated into bills that were enacted (as determined by an automated text analysis, applicable beginning with bills in the 110th Congress).

Bills Sponsored

Issue Areas

Rothfus sponsors bills primarily in these issue areas:

Finance and Financial Sector (46%)Environmental Protection (21%)Health (17%)Economics and Public Finance (8%)Armed Forces and National Security (8%)

Recent Bills

Some of Rothfus’s most recently sponsored bills include...

View All » | View Cosponsors »

Voting Record

Key Votes

Rothfus’s VoteVote Description
No H.R. 1892: Further Extension of Continuing Appropriations Act, 2018; Department of Defense Appropriations Act, 2018; SUSTAIN Care Act of 2018; Honoring Hometown Heroes Act
Feb 9, 2018. Passed 240/186.
This bill became the vehicle for passage of funding for the federal government through March 23, 2018, to avert a government shutdown that would have occurred on February 9, 2018 had this bill not been enacted. The bill was introduced as the Honoring Hometown Heroes ...
Aye S. 612: A bill to designate the Federal building and United States courthouse located at 1300 Victoria Street in Laredo, Texas, as the “George P. Kazen Federal Building ...
Dec 8, 2016. Passed 360/61.
No H.R. 3038: Highway and Transportation Funding Act of 2015, Part II
Jul 15, 2015. Passed 312/119.
No H.R. 2146: Defending Public Safety Employees’ Retirement Act
Jun 18, 2015. Passed 218/208.
This vote made H.R. 2146 the vehicle for passage of Trade Promotion Authority (TPA) for the Trans-Pacific Partnership (TPP) trade deal currently being negotiated. H.R. 2146 was originally introduced as a bill to address issues with retirement funds of federal law enforcement officers and firefighters. ...
Yea H.R. 2048: Uniting and Strengthening America by Fulfilling Rights and Ensuring Effective Discipline Over Monitoring Act of 2015
May 13, 2015. Passed 338/88.
The USA Freedom Act (H.R. 2048, Pub.L. 114–23) is a U.S. law enacted on June 2, 2015 that restored in modified form several provisions of the Patriot Act, which had expired the day before. The act imposes some new limits on the bulk collection of ...
Yea H.R. 83 (113th): Consolidated and Further Continuing Appropriations Act, 2015
Dec 11, 2014. Passed 219/206.
This bill became the vehicle for passage of the Consolidated and Further Continuing Appropriations Act, 2015 [pdf], which was approved by the House on December 11, 2014 and by the Senate on December 13, 2014. The bill was originally introduced on January 3, 2013 by ...
Yea H.R. 4681 (113th): Intelligence Authorization Act for Fiscal Year 2015
Dec 10, 2014. Passed 325/100.
No H.J.Res. 124 (113th): Continuing Appropriations Resolution, 2015
Sep 17, 2014. Passed 319/108.
Nay H.R. 3361 (113th): USA FREEDOM Act
May 22, 2014. Passed 303/121.
No H.R. 3309 (113th): Innovation Act
Dec 5, 2013. Passed 325/91.

Missed Votes

From Jan 2013 to Mar 2018, Rothfus missed 18 of 3,340 roll call votes, which is 0.5%. This is better than the median of 2.3% among the lifetime records of representatives currently serving. The chart below reports missed votes over time.

Show the numbers...

Time PeriodVotes EligibleMissed VotesPercentPercentile
2013 Jan-Mar8911.1%42nd
2013 Apr-Jun21500.0%0th
2013 Jul-Sep20000.0%0th
2013 Oct-Dec13700.0%0th
2014 Jan-Mar14800.0%0th
2014 Apr-Jun21900.0%0th
2014 Jul-Sep14700.0%0th
2014 Nov-Dec4900.0%0th
2015 Jan-Mar14410.7%26th
2015 Apr-Jun24410.4%27th
2015 Jul-Sep13900.0%0th
2015 Oct-Dec17710.6%31st
2016 Jan-Mar13710.7%18th
2016 Apr-Jun20452.5%57th
2016 Jul-Sep23200.0%0th
2016 Nov-Dec4848.3%89th
2017 Jan-Mar20800.0%0th
2017 Apr-Jun13600.0%0th
2017 Jul-Sep19900.0%0th
2017 Oct-Dec16700.0%0th
2018 Jan-Mar10144.0%61st

Primary Sources

The information on this page is originally sourced from a variety of materials, including:

Keith Rothfus is pronounced:

keeth // ROTH-fis

The letters stand for sounds according to the following table:

LetterSounds As In
eemeet
ffat
ipin
kking
otop
rrag
ssit
ththin

Capital letters indicate a stressed syllable.

The House Affordable Medicines Caucus recently launched by Reps. Peter Welch (D-VT) and Keith Rothfus (R-PA) already has plenty of ideas to reform our nation's drug policies and produce cost savings for both the federal government and beneficiaries. The latest edition of Health Affairs(subscription required), though, adds a couple more ideas to encourage more efficient use of prescription drugs.

The first article from authors David Hutton, Paula Anne Newman-Casey, Mrinalini Tavag, David Zacks, and Joshua Stein takes a closer look at two popular drugs, Avastin and Lucentis, used to treat two of the leading causes of blindness. Although the drugs have been shown to have similar effectiveness in government trials and so far seem to have only minor differences in the prevalence of side effects, Lucentis costs 40 times more per dose than Avastin. And these two drugs have been very popular, accounting for $2 billion in Medicare outlays in 2010, or one-sixth of all Part B drug spending, and $500 million in beneficiary spending. In terms of use, Avastin already accounts for two-thirds while Lucentis accounts for one-third.

In their study, the authors estimate that if all Medicare patients were instead prescribed Avastin, taxpayers would save $18 billion and patients $5 billion over ten years, drastically curtailing the share of Part B drug spending consumed by these two drugs, from one-sixth to just 2 percent. If non-Medicare patients were to switch as well, the overall savings would increase by another $6 billion to $29 billion.

The question, then, is how to encourage greater use of Avastin in place of Lucentis. The path of least intervention likely flows through changing the perverse way Medicare reimburses physicians for administering drugs. Currently, physicians are reimbursed for the average sales price (ASP) of the drug plus an add-on intended to compensate for administrative costs equal to 6 percent of the drug's ASP. Tying a physician's reimbursement to the cost of a drug inevitably incentivizes him or her to use the most expensive drug available, regardless of whether a cheaper, therapeutically equivalent alternative is available. And given that 90 percent of Medicare beneficiaries have supplemental insurance that often covers most to all of their cost-sharing responsibility, very few beneficiaries will even pay the extra money the physician's decision would normally entail. Converting the percentage add-on to a flat payment regardless of which drug is administered would do a lot to increase the use of Avastin (and other less costly Part B drugs), as was recommended in the President's budget, by the National Coalition on Health Care, and by the Bipartisan Policy Center.

Or to provide an even stronger incentive, in the case of therapeutically equivalent drugs, Medicare could reimburse only to the ASP plus six percent of the least costly option. Doing this would achieve the full savings that the authors identify but requires Medicare to decide when drugs are perfectly substitutable and specify any exemptions to that dictate.

The chart below shows how drug spending swings depending on which drug is used (ranibizumab is Lucentis, bevacizumab is Avastin).

The second article from Yuting Zhang, Chao Zhou, and Seo Hyon Baik examines the automatic assignment of prescription drug plans to Medicare Part D beneficiaries who receive the Low-Income Subsidy (LIS) and do not voluntarily elect a plan. The LIS assists with premiums and cost-sharing for low-income beneficiaries in Part D. New LIS-eligible enrollees who do not indicate a preferred drug plan and current enrollees whose plan premiums exceed a certain amount are randomly assigned plans. This study attempts to measure the savings for beneficiaries and the government if they were assigned to a plan in their region that would best meet their needs.

They take a random sample of LIS enrollees who were randomly assigned plans in 2009 and compare actual prescription drug spending to the spending that would have occurred if they had been assigned to the plan that would have minimized their costs based on 2008 drug consumption. The authors note some limitations to their study, most notably that they assume no change in drug consumption patterns.

When enrollees are assigned to the optimal plan, the resulting savings to the government amount to $710 per person on average, which translates to $5 billion of spending in 2009. As noted above, the real world savings would be smaller because beneficiaries would change their consumption patterns to some degree based on the benefits of their new plan. In addition, the study looks only at one year, so it excludes any effect from insurance companies adjusting prices or or plan offerings based on policy changes that lead to a different mix of beneficiaries for a given plan. Regardless, policymakers should closely examine the issue of random versus intelligent plan assignment to determine effects on the budget and impacts on the LIS population.

Clearly, opportunities exist to assess Part D and Part B drug policy structure for potential savings, which should be balanced against incentives to innovate and other implications for the health system at large.

Leave a Comment

(0 Comments)

Your email address will not be published. Required fields are marked *